Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 84790A105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Callodine Capital Management, LP
13G/A
Amendment 3
|
7.6% |
8/14/2026
Event 6/30/2026
|
|
| Callodine Capital Management, LP | 7.6% | ||
| James S. Morrow | 7.6% | ||
|
American Century Investment Management, Inc.
13G/A
Amendment 4
|
9.1% |
8/14/2026
Event 6/30/2026
|
|
| American Century ETF Trust | 5.1% | ||
| American Century Investment Management, Inc. | 9.1% | ||
| American Century Companies, Inc. | 9.1% | ||
| Stowers Institute for Medical Research | 9.1% | ||
|
American Century Investment Management, Inc.
13G/A
Amendment 3
|
7.3% |
5/1/2026
Event 3/31/2026
|
|
| American Century Capital Portfolios, Inc. | 2.2% | ||
| American Century Investment Management, Inc. | 7.3% | ||
| American Century Companies, Inc. | 7.3% | ||
| Stowers Institute for Medical Research | 7.3% | ||
| Vanguard Capital Management LLC 13G | 5.1% |
4/30/2026
Event 3/31/2026
|
|
| Vanguard Portfolio Management LLC 13G | 6.4% |
4/29/2026
Event 3/31/2026
|
|
| Vanguard Group Inc 13G/A Amendment 9 | 0% |
3/27/2026
Event 3/13/2026
|
|
|
Callodine Capital Management, LP
13G/A
Amendment 2
|
8.9% |
2/17/2026
Event 12/31/2025
|
|
| Callodine Capital Management, LP | 8.9% | ||
| James S. Morrow | 8.9% | ||
|
Callodine Capital Management, LP
13G/A
Amendment 1
|
7.1% |
11/14/2025
Event 9/30/2025
|
|
| Callodine Capital Management, LP | 7.1% | ||
| James S. Morrow | 7.1% | ||
|
American Century Investment Management, Inc.
13G/A
Amendment 2
|
8.5% |
11/14/2025
Event 9/30/2025
|
|
| American Century Capital Portfolios, Inc. | 5.4% | ||
| American Century Investment Management, Inc. | 8.5% | ||
| American Century Companies, Inc. | 8.5% | ||
| Stowers Institute for Medical Research | 8.5% | ||
| Pzena Investment Management LLC 13G/A Amendment 1 | 10.2% |
10/3/2025
Event 9/30/2025
|
|
|
Callodine Capital Management, LP
13G
|
5.4% |
8/14/2025
Event 6/30/2025
|
|
| Callodine Capital Management, LP | 5.4% | ||
| James S. Morrow | 5.4% | ||
|
American Century Investment Management, Inc.
13G/A
Amendment 1
|
7.3% |
8/14/2025
Event 6/30/2025
|
|
| American Century Investment Management, Inc. | 7.3% | ||
| American Century Companies, Inc. | 7.3% | ||
| Stowers Institute for Medical Research | 7.3% | ||
| BlackRock, Inc. 13G | 7.8% |
7/17/2025
Event 6/30/2025
|
|
| Allspring Global Investments Holdings, LLC 13G/A Amendment 5 | 2.9% |
7/11/2025
Event 6/30/2025
|
|
|
American Century Investment Management, Inc.
13G
|
5.7% |
5/15/2025
Event 3/31/2025
|
|
| American Century Investment Management, Inc. | 5.7% | ||
| American Century Companies, Inc. | 5.7% | ||
| Stowers Institute for Medical Research | 5.7% | ||
| Pzena Investment Management LLC 13G | 5.1% |
4/28/2025
Event 3/31/2025
|
|
| BlackRock, Inc. 13G/A Amendment 1 | 4.5% |
4/25/2025
Event 3/31/2025
|
|
| Allspring Global Investments Holdings, LLC 13G/A Amendment 4 | 5.7% |
4/15/2025
Event 3/31/2025
|
|
|
American Century Investment Management, Inc.
13G/A
Amendment 1
|
4.9% |
2/14/2025
Event 12/31/2024
|
|
| American Century Investment Management, Inc. | 4.9% | ||
| American Century Companies, Inc. | 4.9% | ||
| Stowers Institute for Medical Research | 4.9% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 26 | 302 k | $24.4 M |
| 2026 Q2 | 323 | 29.4 M | $2.37 B |
| 2026 Q1 | 304 | 26.5 M | $1.95 B |
| 2025 Q4 | 276 | 26.5 M | $1.57 B |
| 2025 Q3 | 272 | 25.9 M | $1.36 B |
| 2025 Q2 | 278 | 27.0 M | $1.43 B |
| 2025 Q1 | 313 | 25.9 M | $1.85 B |
| 2024 Q4 | 330 | 25.9 M | $2.18 B |
| 2024 Q3 | 340 | 26.3 M | $2.50 B |
| 2024 Q2 | 321 | 27.0 M | $2.31 B |
| 2024 Q1 | 320 | 29.3 M | $2.60 B |
| 2023 Q4 | 325 | 31.9 M | $2.55 B |
| 2023 Q3 | 316 | 35.7 M | $2.80 B |
| 2023 Q2 | 342 | 42.1 M | $3.29 B |
| 2023 Q1 | 315 | 40.7 M | $2.70 B |
| 2022 Q4 | 285 | 42.6 M | $2.58 B |
| 2022 Q3 | 261 | 39.3 M | $1.54 B |
| 2022 Q2 | 269 | 41.3 M | $3.38 B |
| 2022 Q1 | 283 | 41.3 M | $3.66 B |
| 2021 Q4 | 319 | 39.2 M | $3.98 B |
| 2021 Q3 | 283 | 41.7 M | $3.99 B |
| 2021 Q2 | 298 | 39.9 M | $3.40 B |
| 2021 Q1 | 318 | 40.2 M | $3.42 B |
| 2020 Q4 | 318 | 42.0 M | $3.32 B |
| 2020 Q3 | 297 | 40.6 M | $2.32 B |
| 2020 Q2 | 278 | 41.3 M | $1.89 B |
| 2020 Q1 | 276 | 43.1 M | $1.57 B |
| 2019 Q4 | 352 | 46.9 M | $3.01 B |
| 2019 Q3 | 317 | 53.7 M | $2.83 B |
| 2019 Q2 | 247 | 52.0 M | $2.80 B |
| 2019 Q1 | 226 | 54.1 M | $2.96 B |
| 2018 Q4 | 254 | 53.8 M | $2.28 B |
| 2018 Q3 | 267 | 52.4 M | $3.91 B |
| 2018 Q2 | 15 | 2.34 M | $51.5 M |
| 2016 Q1 | 1 | 6.00 | $0 |